Composition:
Each tablet contains:
active substance 150 mg of ranitidine hydrochloride salt (equivalent to 168 mg of ranitidine hydrochloride)
excipients: citrate, monosodium, sodium benzoate, aspartame, sodium bicarbonate, povidone K-25, macrogol 6000, flavor, grapefruit, orange flavor , natural colorant.
1 tablet contains 328 mg of sodium.
Action:
The drug inhibits basal and stimulated gastric acid secretion by parietal cells in the gastric mucosa. Absorbed from the gastrointestinal tract. Operation of a single tablet formulation begins within a few minutes and lasts for 12 hours. Peak plasma concentrations occur after about 2 hours.
Indications:
- treatment of ulcers of the stomach and duodenum;
- prevention and treatment of gastric and duodenal ulcers, occurring during the use of
non-steroidal anti-inflammatory drugs;
-owrzodzenie occurring after stomach operations (anastomotic ulcer);
- Zollinger - Ellison syndrome;
- gastroesophageal reflux disease;
- alleviation of symptoms of recurrent dyspepsia not associated with evidence of organic disease
of the gastrointestinal tract;
- prevention of stress ulcers in critically ill patients;
- prevention of Mendelson syndrome (aspiration of gastric acid before
general anesthesia in patients in whom there is such a risk).
Dosage:
Adults:
gastric ulcer and duodenal ulcer, gastric postoperative treatment - one tablet of 150 mg two times a day, morning and evening, or a single 300 mg at bedtime. In most patients, healing of the ulcer after 4 weeks. Patients who have not healed ulcer at this stage of treatment, healing usually occurs during the ensuing 4 weeks. Prevention of relapse of peptic ulcer - one tablet of 150 mg at bedtime
sores occurring during the use of nonsteroidal anti-inflammatory drug treatment - one tablet of 150 mg two times a day or 300 mg once at night, for a period of 8 to 12 weeks. Prevention - one tablet of 150 mg two times a day.
gastro - disease, alleviation of symptoms - one tablet of 150 mg two times daily for up to two weeks. If necessary, treatment can be extended for a further two weeks.
Reflux esophagitis - the recommended dosage is 150 mg two times a day, or a single 300 mg at bedtime for a period of 8 to 12 weeks. In patients with severe esophagitis dose of ranitidine may be increased to 4 times daily 150 mg. Treatment should last for the 12 weeks. In the maintenance treatment of reflux oesophagitis, the recommended dose is 150 mg two times a day.
recurrent dyspepsia - one tablet of 150 mg, if necessary, two times daily for up to 6 weeks.
prevention of stress ulceration in seriously ill patients - one tablet of 150 mg at bedtime
Zollinger - Ellison Syndrome - A starting dose of 150 mg three times daily and, if necessary, can be increased to 600 - 900 mg per day.
preventing syndrome Mendelson - 150 mg in the evening before anesthesia and 150 mg 2 hours before anesthesia.
Children:
treatment of gastric ulcers - recommended oral dose is from 2 to 4 mg / kg two times a day. Do not exceed the dose of 300 mg daily.